Skip to main content
. Author manuscript; available in PMC: 2019 Jun 19.
Published in final edited form as: Genes Immun. 2018 Dec 19:10.1038/s41435-018-0052-x. doi: 10.1038/s41435-018-0052-x

Figure 2. Interaction between Bcl-2 and its inhibitor Navitoclax (ABT-263).

Figure 2

Navitoclax is an oral form of Bcl-2 inhibitor that showed efficacy in BCL2-overexpressing CLL and in follicular lymphoma. Molecular docking analysis shows navitoclax interaction in the binding site of Bcl-2. The inhibitor is shown as a ball and stick, while Bcl-2 is shown in a space filling (a) and ribbon diagram (b) model.